Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial

BACKGROUND: Trimetazidine is a metabolic anti-ischemic agent, which increases the tolerance of cardiomyocytes to ischemia. However, few studies have explored the effect of trimetazidine on ventricular remodeling in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC Cardiovasc Disord
Hauptverfasser: Wu, Lili, Luan, Yi, Li, Ya, Wang, Min, He, Jialin, Jin, Chongying, Zhang, Wenbin
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2020
Schlagworte:
Study Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7275498/
https://ncbi.nlm.nih.gov/pubmed/32503494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12872-020-01557-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge